Development of a novel patient-reported measure for acromegaly: the Acro-TSQ

Maria Fleseriu, Leon Fogelfeld, Murray B. Gordon, Jill Sisco, Hilary H. Colwell, William H. Ludlam, Asi Haviv, Susan D. Mathias

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but there are no validated PRO measures available that focus on the disease burden and the impact of treatment, specifically designed for use in patients with acromegaly. We sought to develop a new and unique PRO measure, the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ). Methods: Concept elicitation (CE) interviews were conducted with acromegaly patients in the United States receiving SSA injections at a stable dose for ≥ 6 months. A questionnaire was drafted based on these interviews; combined CE and cognitive debriefing (CE/CD) interviews were then conducted to confirm the content, clarity, and relevance of the questionnaire. Results: Nineteen subjects completed interviews [n = 9 CE, n = 10 CE/CD; n = 15 Lanreotide Depot/Autogel (Somatuline), n = 4 Octreotide LAR (Sandostatin LAR)]. Most subjects responded positively when asked about the effectiveness of their current treatment; however, breakthrough symptoms, injection site reactions, and side effects were commonly reported and had negative impacts on social and emotional well-being and daily activities. All 10 subjects involved in debriefing interviews found the questionnaire to be relevant, easy to complete, and found the response options to be clear. The resulting 26-item Acro-TSQ covers symptoms and symptom control, gastrointestinal side effects and their impact on daily activities, the emotional impact of treatment, convenience and ease of use, and overall satisfaction. Conclusions: The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.

Original languageEnglish (US)
JournalPituitary
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Acromegaly
Interviews
Somatostatin
Therapeutics
Octreotide
Injections
Surveys and Questionnaires
Subcutaneous Injections
Outcome Assessment (Health Care)

Keywords

  • Acro-TSQ
  • Acromegaly
  • Patient reported outcomes
  • Quality of life
  • Questionnaire

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Fleseriu, M., Fogelfeld, L., Gordon, M. B., Sisco, J., Colwell, H. H., Ludlam, W. H., ... Mathias, S. D. (Accepted/In press). Development of a novel patient-reported measure for acromegaly: the Acro-TSQ. Pituitary. https://doi.org/10.1007/s11102-019-00986-4

Development of a novel patient-reported measure for acromegaly : the Acro-TSQ. / Fleseriu, Maria; Fogelfeld, Leon; Gordon, Murray B.; Sisco, Jill; Colwell, Hilary H.; Ludlam, William H.; Haviv, Asi; Mathias, Susan D.

In: Pituitary, 01.01.2019.

Research output: Contribution to journalArticle

Fleseriu, M, Fogelfeld, L, Gordon, MB, Sisco, J, Colwell, HH, Ludlam, WH, Haviv, A & Mathias, SD 2019, 'Development of a novel patient-reported measure for acromegaly: the Acro-TSQ', Pituitary. https://doi.org/10.1007/s11102-019-00986-4
Fleseriu, Maria ; Fogelfeld, Leon ; Gordon, Murray B. ; Sisco, Jill ; Colwell, Hilary H. ; Ludlam, William H. ; Haviv, Asi ; Mathias, Susan D. / Development of a novel patient-reported measure for acromegaly : the Acro-TSQ. In: Pituitary. 2019.
@article{653d9332711a4112998891b810c3d169,
title = "Development of a novel patient-reported measure for acromegaly: the Acro-TSQ",
abstract = "Purpose: Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but there are no validated PRO measures available that focus on the disease burden and the impact of treatment, specifically designed for use in patients with acromegaly. We sought to develop a new and unique PRO measure, the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ). Methods: Concept elicitation (CE) interviews were conducted with acromegaly patients in the United States receiving SSA injections at a stable dose for ≥ 6 months. A questionnaire was drafted based on these interviews; combined CE and cognitive debriefing (CE/CD) interviews were then conducted to confirm the content, clarity, and relevance of the questionnaire. Results: Nineteen subjects completed interviews [n = 9 CE, n = 10 CE/CD; n = 15 Lanreotide Depot/Autogel (Somatuline), n = 4 Octreotide LAR (Sandostatin LAR)]. Most subjects responded positively when asked about the effectiveness of their current treatment; however, breakthrough symptoms, injection site reactions, and side effects were commonly reported and had negative impacts on social and emotional well-being and daily activities. All 10 subjects involved in debriefing interviews found the questionnaire to be relevant, easy to complete, and found the response options to be clear. The resulting 26-item Acro-TSQ covers symptoms and symptom control, gastrointestinal side effects and their impact on daily activities, the emotional impact of treatment, convenience and ease of use, and overall satisfaction. Conclusions: The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.",
keywords = "Acro-TSQ, Acromegaly, Patient reported outcomes, Quality of life, Questionnaire",
author = "Maria Fleseriu and Leon Fogelfeld and Gordon, {Murray B.} and Jill Sisco and Colwell, {Hilary H.} and Ludlam, {William H.} and Asi Haviv and Mathias, {Susan D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11102-019-00986-4",
language = "English (US)",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Development of a novel patient-reported measure for acromegaly

T2 - the Acro-TSQ

AU - Fleseriu, Maria

AU - Fogelfeld, Leon

AU - Gordon, Murray B.

AU - Sisco, Jill

AU - Colwell, Hilary H.

AU - Ludlam, William H.

AU - Haviv, Asi

AU - Mathias, Susan D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but there are no validated PRO measures available that focus on the disease burden and the impact of treatment, specifically designed for use in patients with acromegaly. We sought to develop a new and unique PRO measure, the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ). Methods: Concept elicitation (CE) interviews were conducted with acromegaly patients in the United States receiving SSA injections at a stable dose for ≥ 6 months. A questionnaire was drafted based on these interviews; combined CE and cognitive debriefing (CE/CD) interviews were then conducted to confirm the content, clarity, and relevance of the questionnaire. Results: Nineteen subjects completed interviews [n = 9 CE, n = 10 CE/CD; n = 15 Lanreotide Depot/Autogel (Somatuline), n = 4 Octreotide LAR (Sandostatin LAR)]. Most subjects responded positively when asked about the effectiveness of their current treatment; however, breakthrough symptoms, injection site reactions, and side effects were commonly reported and had negative impacts on social and emotional well-being and daily activities. All 10 subjects involved in debriefing interviews found the questionnaire to be relevant, easy to complete, and found the response options to be clear. The resulting 26-item Acro-TSQ covers symptoms and symptom control, gastrointestinal side effects and their impact on daily activities, the emotional impact of treatment, convenience and ease of use, and overall satisfaction. Conclusions: The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.

AB - Purpose: Somatostatin analogs (SSAs) represent a mainstay of medical treatment for acromegaly, currently available as either intramuscular or deep subcutaneous injections. Patient-reported outcomes (PROs) are increasingly common as relevant outcomes in studies of acromegaly and its treatment, but there are no validated PRO measures available that focus on the disease burden and the impact of treatment, specifically designed for use in patients with acromegaly. We sought to develop a new and unique PRO measure, the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ). Methods: Concept elicitation (CE) interviews were conducted with acromegaly patients in the United States receiving SSA injections at a stable dose for ≥ 6 months. A questionnaire was drafted based on these interviews; combined CE and cognitive debriefing (CE/CD) interviews were then conducted to confirm the content, clarity, and relevance of the questionnaire. Results: Nineteen subjects completed interviews [n = 9 CE, n = 10 CE/CD; n = 15 Lanreotide Depot/Autogel (Somatuline), n = 4 Octreotide LAR (Sandostatin LAR)]. Most subjects responded positively when asked about the effectiveness of their current treatment; however, breakthrough symptoms, injection site reactions, and side effects were commonly reported and had negative impacts on social and emotional well-being and daily activities. All 10 subjects involved in debriefing interviews found the questionnaire to be relevant, easy to complete, and found the response options to be clear. The resulting 26-item Acro-TSQ covers symptoms and symptom control, gastrointestinal side effects and their impact on daily activities, the emotional impact of treatment, convenience and ease of use, and overall satisfaction. Conclusions: The Acro-TSQ is a novel PRO, focused on both disease burden and impact of treatment; it was found to be comprehensive, clear, and relevant for patients with acromegaly receiving injectable SSA treatment.

KW - Acro-TSQ

KW - Acromegaly

KW - Patient reported outcomes

KW - Quality of life

KW - Questionnaire

UR - http://www.scopus.com/inward/record.url?scp=85073960331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073960331&partnerID=8YFLogxK

U2 - 10.1007/s11102-019-00986-4

DO - 10.1007/s11102-019-00986-4

M3 - Article

C2 - 31522359

AN - SCOPUS:85073960331

JO - Pituitary

JF - Pituitary

SN - 1386-341X

ER -